Despite conflicting results, there are warnings associated with initiating therapy with SGLT2 inhibitors while patients have active diabetic foot wounds, prior amputations, or significant peripheral arterial disease based on the American College of Cardiology (ACC) guidelines [22]. The gene discussed is SLC5A2; the disease is peripheral arterial disease.